Asthma Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Anti-Inflammatory, Bronchodilators, Combination Therapies, Others); By Device Type; By Route of Administration; By Region; Segment Forecast, 2022 - 2030
- Published Date:Jul-2022
- Pages: 119
- Format: PDF
- Report ID: PM1305
- Base Year: 2021
- Historical Data: 2018 - 2020
Report Outlook
The global asthma treatment market was valued at USD 17.85 billion in 2021 and is expected to grow at a CAGR of 4.6% during the forecast period. The expanding rates of respiratory illnesses combined with the interest for financially developed treatment choices are supposed to drive the development of the asthma treatment market.
Know more about this report: Request for sample pages
Furthermore, factors including the rising indoor and open-air causative specialists including contamination, allergens, and residue, combined with the changing ways of life that impact the frequencies of asthma, are also filling the interest for asthma treatment over the forecast period. This is credited to the conventional disintegration by driving brands like Advair and Symbicort. Then again, expanding frequencies of respiratory sicknesses combined with the interest in financial therapy choices is expected to drive the asthma treatment market during the forecast period.
As per the appraisals distributed by the Global Initiative for Asthma (GINA), in 2013, around 300 million patients universally were distressed with this illness, and the number is supposed to fill before very long. This is one of the urgent purposes behind expanding the reception of asthma treatment worldwide. Besides, factors, for example, the rising indoor and open-air causative specialists including contamination, allergens, and residue, among others, combined with the changing ways of life that impact asthma frequencies are filling the interest for treatment over the projected period.
Nonetheless, a decrease in the asthma treatment market development is anticipated during the conjecture time frame because of the patent lapse of driving brands, for example, Advair and Symbicort, in January and November 2018 separately. Moreover, the deferred commercialization and promotion of asthma nonexclusive options in the market are supposed to be an additional reason for a downturn on the lookout.
Know more about this report: Request for sample pages
Industry Dynamics
Growth Drivers
Some market factors like the focus on spreading awareness about asthma treatment, including standard treatment choices, for example, compressed meter portion inhalers and dry powder inhalers, are empowering the market. Increased adoption rate due to the high efficacy of long-acting muscarinic adversary inhaled corticosteroid, long-acting beta2 agonist-inhaled corticosteroid, and other combination indications, and late administrative endorsements have impelled the reception of blend treatment in the market. The rising focus on brilliant or advanced inhalers for the organization of asthma drugs is driving the worldwide market.
The asthma treatment market is expected to be driven by expansion in item endorsements by the FDA and other administrative bodies, ascend in the predominance of asthma, and vital methodologies like coordinated efforts and organizations by market players. Ascend in the open doors for market players to extend their geographical presence in arising nations will fuel the development of the market.
Report Segmentation
The market is primarily segmented based on drug class, device type, route of administration, and region.
|
By Drug Class |
By Device Type |
By Route Of Administration |
By Region |
|
|
|
|
Know more about this report: Request for sample pages
The Combination Therapy Fragment to Rule the Market
Based upon drug class, the combination therapy fragment incorporating inhaled corticosteroids with long-acting beta-agonists is expected to rule the market during the forecast period. The course includes the accompanying advantages: upgraded remedial impact, broad accessibility, and improved patient drug adherence. The high viability and reception paces of asthma treatment connected with the double activity blend treatment represented the more significant income share when contrasted with the other medication mixes. Additionally, the rising innovative work endeavors relating to improving novel biologics, for example, Duplimab and Lebrikizumab, related to the expected sendoff of pipeline items, including Cinqair (reslizumab), during the projected period is likely to contribute towards the development of combination drugs market segment.
Dry Powder Inhalers to Showcase the Fastest Growth
The inhaler fragment incorporates dry powder, metered portion, and delicate fog inhalers. The metered-portion inhalers (MDIs) fragment ruled the general market in forecast time. This is significantly credited to unwavering quality, adaptability, self-control, simple accessibility, convey ability, and cost-effective clinical spray conveyance choice. Expanding prerequisites for crisis treatment choices pointed against unexpected asthma assaults and versatile gadgets comprise the pivotal determinants contributing towards the most significant portion of the overall market moved by the dry powder inhalers (DPIs) item section.
The nebulizer conveys the medication in a fluid structure, which is apportioned by the compacted air. The ideal plan of the nebulizers works with the organization of drugs in disabled, geriatric, and pediatric patients. Blower, ultrasonic, and work nebulizers address the significant kinds of nebulizers accessible financially. These gadgets show critical advantages in the home medical services as most would consider it normal to furnish this portion with future learning experiences. Nebulizers are a little convenient and can apportion prescription straightforwardly into the respiratory plot. These related advantages are supposed to support their utilization rates from now on.
The Inhaled Drugs Section Holds the Most Significant Sector in the Market Growth
The inhaled drugs section held the most significant piece of the pie to the higher penetration rates and better quiet medicine consistency of pulmonary drug conveyance frameworks in treatment plans. The increased patient awareness levels of alternative asthma helpful choices and convenience related to these upgraded drug conveyance frameworks are acquiring noticeable quality accordingly, reassuring the fragment development over the conjecture period.
Geographic Overview
North America is expected to rule the asthma treatment market during the forecast period. The heightened occurrence pace of asthma expanded mindfulness levels relating to treatment choices, and the rising reception of inhaled treatment is a portion of the central point crediting the most considerable income portion of this region. The European market is set to observe consistent development predominantly because of an extensively evolved drug market and the tremendous interest in treatment. The rising geriatric populace, vulnerable to procure respiratory circumstances, for example, asthma, will additionally uphold the development of the territorial market in the U.S.
The Asia Pacific is anticipated to grow at the fastest pace throughout the forecast period due to the expanding asthma predominance and the interest in financially savvy treatment choices for patients.
Competitive Insight
Some of the major players operating the asthma treatment market include Abbott, Amgen, AstraZeneca plc., Biogen, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., Merck & Co., Inc., Mylan N.V., Novartis AG, Roche AG, Sanofi, Sunovion Pharmaceuticals, Inc., and Teva Pharmaceutical Industries.
Recent developments
- In January 2022, GSK received approval from the FDA for a 40 mg pre-filled needle of Nucala for kids aged 6-11 years with extreme eosinophilic asthma. Nucala is an extra remedy upkeep treatment for patients six years and more seasoned with severe eosinophilic asthma.
- In December 2021, AstraZeneca and Amgen's Tezspire got approval in the U.S. for the add-on maintenance treatment of adults and pediatric patients 12 and more suffering from severe asthma. This is 1st biological treatment that was demonstrated at the highest point of the fiery outpouring by focusing on thymic stromal lymphopoietin (TSLP). It is the first and only biologic to reliably and fundamentally decrease asthma intensifications across Phase II and III clinical preliminaries, which incorporated a broad populace of severe patients regardless of key biomarkers, including blood eosinophil counts and unfavorably susceptible status and fragmentary breathed out nitric oxide (FeNO).
- In July 2021, AstraZeneca's BLA for tezepelumab was acknowledged and allowed Priority Review for the treatment by the FDA. AstraZeneca is creating Tezepelumab in collaboration with Amgen.
Asthma Treatment Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2021 |
USD 17.85 billion |
|
Revenue forecast in 2030 |
USD 26.10 billion |
|
CAGR |
4.6% from 2022 - 2030 |
|
Base year |
2021 |
|
Historical data |
2018 - 2020 |
|
Forecast period |
2022 - 2030 |
|
Quantitative units |
Revenue in USD billion and CAGR from 2022 to 2030 |
|
Segments covered |
By Drug Class, By Device Type, By Route of Administration, By Region |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
|
Key companies |
Abbott, Amgen, AstraZeneca plc., Biogen, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., Merck & Co., Inc., Mylan N.V., Novartis AG, Roche AG, Sanofi, Sunovion Pharmaceuticals, Inc., and Teva Pharmaceutical Industries. |
© 2024 Polaris Market Research and Consulting. All rights reserved
